Product Details
| Product Name: Rucaparib | CAS No.: 1859053-21-6 |
| Min. Order: 1KG | Purity: 99% |
| Supply Ability: 5000KG | Release date: 2021/04/16 |
Treatment for three indications: Rubraca was the first PARP inhibitor approved for the treatment of prostate cancer. The approval marks Rubraca's third regulatory approval in the United States, following previous indications for monotherapy for recurrent ovarian cancer and monotherapy for ovarian cancer with BRCA mutations (germline and/or somatic cells).
Company Profile Introduction
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-07-03 | ||
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
| $47.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-22 | |
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
|
VIP4Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2025-04-04 | ||
| $1.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-07-06 |
China- Since: 2014-02-11
- Address: A06,4th Floor,Shengboya Business Center,Sanlian Road,Longhua Street,Longhua District,Shenzhen
INQUIRY